Treatment of Crohn's Disease With Peroral 5-Aminosalicylic Acid

Duration of treatment with 5-aminosalicylic acid compounds.

The development of 5-aminosalicylic acid (5-ASA) therapy as a life long treatment for ulcerative colitis is reviewed from its origins in the 1940s to the present day. The drug was designed to treat rheumatoid arthritis, but was found helpful in the management of nine patients with ulcerative colitis. This discovery preceded the emergence of the clinical trial as a tool for assessing a new drug'...

Nephrotic syndrome after treatment with 5-aminosalicylic acid.

reduced during the first six months by non-closure of the defect. Presumably non-closure allows cerebrospinal fluid to escape from the open neural tube, postponing the development of hydrocephalus until epithelium has formed. As deferred shunt operations are associated with a better prognosis,4 nonclosure may in fact be advantageous, delaying the onset of ventriculitis until the child is immuno...

Role of 5-aminosalicylic acid (5-ASA) in treatment of inflammatory bowel disease: a systematic review.

Authors' objectives To perform a systematic review of the efficacy of 5-aminosalicylic acid (5-ASA) compounds (oral and topical) in the treatment of inflammatory bowel disease (IBD), both ulcerative colitis (UC) and Crohn's disease (CD), in the acute phase for inducing remission and for the prevention of relapses or recurrences. Also, to evaluate the influence of several factors (such as dosage...

aminosalicylic acid to 5-aminosalicylic acid in topical treatment of ulcerative colitis. Digestion

Synthesis and evaluation of a prodrug of 5-aminosalicylic acid for the treatment of ulcerative colitis

Objective(s): This study is aimed to design and synthesize a prodrug of 5-aminosalicylic acid and evaluate its ameliorative effect on experimental ulcerative colitis (UC).Materials and Methods: 5-Aminosalicylic acid-alanine (5-ASA-ALA) was synthesized and characterized. Its stability study was conducted in rat plasma and in the gastroint...